RxDoctor Payments Data

Honling Yuen, MD

Internal Medicine · Dallas, TXNPI 1508808825

Payments from drug & device makers

$1,410in general payments, 2019–2025

Across 76 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$224
  • Boehringer Ingelheim$192
  • Exact Sciences$190
  • AbbVie$161
  • GSK$118
  • AstraZeneca$107
  • plus $418 from 14 others

What the payments were for

  • Food & beverage$1,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,410 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$121,584
Medicare patients
141
Services billed
3,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$50,166
OzempicSemaglutide18$34,970
EliquisApixaban22$32,413
MounjaroTirzepatide18$22,649
SynjardyEmpagliflozin/Metformin Hcl21$20,867
XareltoRivaroxaban11$14,444
ShingrixVaricella-Zoster Ge/As01b/Pf26$5,770
Breo ElliptaFluticasone/Vilanterol11$4,261
ArexvyRsvpref3 Antigen/As01e/Pf13$4,089
Rosuvastatin Calcium294$3,180
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen57$2,253
Nebivolol Hcl21$2,093
Gabapentin64$1,606
Levothyroxine Sodium181$1,596
Tamsulosin Hcl61$1,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$192$71,03363 claims
Novo NordiskOzempic$224$34,97018 claims
PfizerEliquis$44$32,41322 claims
Lilly USA, LLCMounjaro$63$22,64918 claims
GSKShingrix, Breo Ellipta, Arexvy$118$14,11950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →